OF
ALNY icon

Optimize Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Optimize Financial’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$415K Sell
1,377
-4
-0.3% -$1.21K 0.15% 200
2026
Q1 		$457K Buy
+1,381
New +$470K 0.22% 136

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Optimize Financial's ALNY Position: Q2 2026 in Review

Optimize Financial reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.29% in Q2 2026, selling an estimated $1.21K and leaving 1,377 shares worth $415K. The position accounts for 0.15% of the portfolio, ranked #200.

Optimize Financial first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. The position peaked at $457K in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Optimize Financial held 1,377 shares of Alnylam Pharmaceuticals worth $415K as of Q2 2026.
  • Optimize Financial sold 4 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.21K.
  • Alnylam Pharmaceuticals made up 0.15% of Optimize Financial's portfolio in Q2 2026, its #200 holding.
  • Optimize Financial first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Optimize Financial's Alnylam Pharmaceuticals position peaked at $457K in Q1 2026.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Optimize Financial's 13F filing for Q2 2026, filed 27 Aug 2026.